Vineland-3 Growth Scale Values: Psychometric Properties for Clinical Trial Readiness in SCN2A

被引:0
|
作者
Kaat, Aaron J. [1 ]
Evans, Lindsey [2 ]
Nili, Amanda N. [1 ]
Paltell, Katherine [3 ]
Kaiser, Arielle [3 ]
Anderson, Erica
Myers, Leah Schust [4 ]
Berg, Anne T. [1 ,4 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[2] IIT, Chicago, IL USA
[3] Univ Illinois, Chicago, IL USA
[4] FamilieSCN2A Fdn, Gettysburg, PA USA
关键词
SCN2A; Vineland-3; psychometrics; adaptive behavior; FUNCTION CLASSIFICATION-SYSTEM; ADAPTIVE-BEHAVIOR; DRUG DEVELOPMENT; RELIABILITY; CANNABIDIOL; SEIZURES; CHILDREN; ONSET;
D O I
10.1089/cap.2024.0107
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose: The Vineland Adaptive Behavior Scales-3rd Edition (Vineland-3) is one of the most used measures of adaptive behavior among those with sodium channel protein type 2 subunit alpha related disorders (SCN2A-RDs). Several disease-modifying treatments are in early trials for SCN2A-RDs, and as such, clinical outcome assessments (COAs) are necessary. The Vineland-3 introduced growth scale values (GSVs), which are useful for measuring within-person change and thus may be useful in future clinical trials. The purpose of this study was to evaluate the psychometric properties of the Vineland-3 GSVs in SCN2A-RDs in preparation for future clinical trials. Methods: A sample of 65 individuals with SCN2A-RDs (mean = 108, SD = 76.0 months) was recruited for a clinical trial readiness study. The Vineland-3 Comprehensive Interview was administered by trained raters at regular intervals. Multiple psychometric properties were evaluated, including floor and ceiling effects, split-half internal consistency, test-retest reliability, and inter-rater reliability (on approximately 20% of all completions). Results: Floor effects were relatively infrequent on the GSV metric but occurred on all subdomains using the norm-referenced v-scale metric. Split-half and test-retest reliability were excellent for all subdomains (r(xx) >0.95 and inter-class correlation coefficient [ICC] >0.90, respectively), except for coping, which still maintained adequate reliability (r(xx) = 0.87, ICC = 0.65). Inter-rater reliability was also very strong, though it was more variable (alpha(kripp) range 0.78-1.00). Conclusion: The Vineland-3 holds great potential as a COA in SCN2A-RDs; it exhibited very strong psychometric properties in this sample. This is a prerequisite level of evidence needed to demonstrate that a measure is fit-for-purpose for future clinical trials. While some reliability was high, some domains (e.g., domestic) still exhibited problems related to floor effects, which may suggest that they are less relevant to this population. Future studies should expand on this with mixed-methods research for prioritizing concepts of interest on the Vineland-3.
引用
收藏
页数:8
相关论文
共 34 条
  • [21] Pain in older persons with severe dementia. Psychometric properties of the Mobilization-Observation-Behaviour-Intensity-Dementia (MOBID-2) Pain Scale in a clinical setting
    Husebo, Bettina S.
    Strand, Liv I.
    Moe-Nilssen, Rolf
    Husebo, Stein B.
    Ljunggren, Anne E.
    SCANDINAVIAN JOURNAL OF CARING SCIENCES, 2010, 24 (02) : 380 - 391
  • [22] Psychometric properties of Parenting and Family Adjustment Scale (PAFAS) in a Turkish sample with parents of 2-12 years old children from both community and clinical sample
    Guller, Baris
    Guvenir, Taner
    Buran, Burcin Seyda
    Aydemir, Omer
    Varol, Fatma
    Ozbek, Aylin
    Kidak, Ozlem Gencer
    KLINIK PSIKIYATRI DERGISI-TURKISH JOURNAL OF CLINICAL PSYCHIATRY, 2020, 23 (04): : 464 - 475
  • [23] 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas
    Tabouret, Emeline
    Furtner, Julia
    Graillon, Thomas
    Silvani, Antonio
    Le Rhun, Emilie
    Soffietti, Riccardo
    Lombardi, Giuseppe
    Sepulveda, Juan Manuel
    Brandal, Petter
    Brazil, Lucy
    Bendszus, Martin
    Golfinopoulos, Vassilis
    Gorlia, Thierry
    Weller, Michael
    Sahm, Felix
    Wick, Wolfgang
    Preusser, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas
    Tabouret, Emeline
    Furtner, Julia
    Graillon, Thomas
    Silvani, Antonio
    Le Rhun, Emilie
    Soffietti, Riccardo
    Lombardi, Giuseppe
    Sepulveda-Sanchez, Juan Manuel
    Brandal, Petter
    Bendszus, Martin
    Golfinopoulos, Vassilis
    Gorlia, Thierry
    Weller, Michael
    Sahm, Felix
    Wick, Wolfgang
    Preusser, Matthias
    NEURO-ONCOLOGY, 2024, 26 (07) : 1302 - 1309
  • [25] Consistently High Agreement Between Independent Raters of Niemann-Pick Type C1 Clinical Severity Scale in Phase 2/3 Trial
    Farhat, Nicole
    Bailey, Laurie
    Friedmann, Katherine
    Bushnell, Donald M.
    Rodriguez, Danielle
    Berry-Kravis, Elizabeth
    Porter, Forbes D.
    PEDIATRIC NEUROLOGY, 2022, 127 : 32 - 38
  • [26] Intuitive Eating Scale-2: psychometric properties and clinical norms among individuals seeking treatment for an eating disorder in private practice (Jan, 10.1007/s40519-021-01326-x, 2022)
    Babbott, Katie M.
    Mitchison, Deborah
    Basten, Chris
    Thornton, Chris
    Hay, Phillipa
    Byrne, Sue
    Goldstein, Mandy
    Heruc, Gabriella
    van der Werf, Bert
    Consedine, Nathan S.
    Roberts, Marion
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2022, 27 (06) : 2271 - 2272
  • [27] THE ISOTYPE SERIES CS3X[Y2(SCN)7] (X=SR,BA - Y=CU,AG) - CRYSTAL-GROWTH, CRYSTAL-STRUCTURE AND ELECTROOPTIC AND ELECTROSTRICTIVE PROPERTIES
    BOHATY, L
    FROHLICH, R
    ZEITSCHRIFT FUR KRISTALLOGRAPHIE, 1985, 170 (1-4): : 17 - 17
  • [28] Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial.
    Bharucha, Kamal N.
    Brunner, Hermine I.
    Ruperto, Nicola
    Cabral, David A.
    Gedalia, Abraham
    Gerloni, Valeria
    Jorgensen, Christian
    Ramanan, Athimalaipet
    Lovell, Daniel
    Martini, Alberto
    Frane, James
    Wells, Chris
    De Benedetti, Fabrizio, Sr.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S117 - S117
  • [29] CATCH-UP GROWTH DURING TOCILIZUMAB THERAPY FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 2-YEAR DATA FROM A PHASE 3 CLINICAL TRIAL
    De Benedetti, F.
    Ruperto, N.
    Espada, G.
    Gerloni, V.
    Flato, B.
    Horneff, G.
    Myones, B.
    Onel, K.
    Frane, J.
    Wang, J.
    Lipman, T.
    Bharucha, K.
    Martini, A.
    Lovell, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 729 - 730
  • [30] CATCH-UP GROWTH DURING TOCILIZUMAB THERAPY FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 2-YEAR DATA FROM A PHASE 3 CLINICAL TRIAL
    De Benedetti, F.
    Ruperto, N.
    Espada, G.
    Gerloni, V.
    Flato, B.
    Horneff, G.
    Myones, B. L.
    Onel, K.
    Frane, J.
    Wang, J.
    Lipman, T. H.
    Bharucha, K. N.
    Martini, A.
    RHEUMATOLOGY, 2014, 53 : 1 - 1